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Abstract  
BACKGROUND: Diabetic neuropathic pain (DNP) is one of the most difficult types of pain to treat.  
Many studies emphasized on the role of microglial cells, oxidative stress (OS) and inflammatory 
cytokines (IC) in the development of diabetic neuropathy (DN).  
AIM: Present study was designed to evaluate the effect of kaempferol in attenuation of DN in mice.   
METHODS: Diabetes was induced in mice by i.p. injection of a single dose of streptozotocin (STZ) 
(200 mg/kg). Cold allodynia, thermal hyperalgesia and chemical hyperalgesia were assessed, as 
well as markers of inflammation and OS.  
RESULTS: Diabetic mice (DM) showed an increased pain sensation, IC and OS accompanied with 
reduced body weigh gain. Treatment of DM with kaempferol (25, 50 and 100 mg/kg/day/orally) 
attenuated the development of DN and reduced pain sensation. Moreover, it reduced interleukin-1β 
(IL-1β), tumor necrosis factor-α (TNF-α), lipid peroxidation and nitrite, concomitant with the 
improvement of antioxidant defense and body weight gain. In contrast, kaempferol (100 mg/kg) had 
no effects on the behavioral and biochemical parameters. Our results strongly suggest that 
activated microglia, IC and OS are involved in the development of DN.  
CONCLUSIONS: Kaempferol attenuates the development of DNP in mice probably by inhibition of 
neuroimmune activation of microglia and, partly mediated by reducing IC and OS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Diabetic peripheral neuropathy is the most 
common complication of diabetes mellitus and 
characterized by pain, allodynia, hyperalgesia, 
dysthesias, parasthesias, foot ulcers and amputations 
and it was estimated that about 50 % of peoples with 
diabetes have some degree of neuropathic pain (NP) 
[1]. Several data indicate that involvement of 
oxidative-nitrosative stress due to generation of 
advanced glycation end products [1], mitochondrial 
dysfunction [2] and activation of nuclear factor-κB 
Abo-Salem OM. Kaempferol Attenuates Diabetic Neuropathy 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Sep 15; 2(3):424-430.                                                                                                                                                                         425 
 
(NF-κB) in the development of DN [3].  
Reactive oxygen species (ROS) sensitize 
nociceptors, which respond more vigorously to the 
noxious stimuli and start to respond to normally sub-
threshold stimuli. This peripheral sensitization not only 
induces pain directly, but also induces central 
sensitization in the spinal cord, which indirectly 
contributes to pain as well [4]. Superoxide and 
peroxynitrite mediates pain that accompanies 
inflammation and implicated in diabetes-induced 
motor and, sensory nerve conduction deficits and 
peripheral nerve energy deficiency [5]. Moreover, 
studies implicate infiltration and activation of 
inflammatory cells as well as pro-IC (proinflammatory 
cytokines) such as IL-1β and TNF-α [6, 7] which 
causes neuronal hypersensitization. Pain has been 
thought to arise primarily from the dysfunction of 
neurons and activation of non-neuronal cells 
(microglia and astrocytes); that plays an important role 
in central sensitization [8]. Previous studies have 
demonstrated that activation of glial cells, particularly 
microglia in spinal cord [9], retina [10] and 
hypothalamus [11] in hyperglycemia. Activated 
microglia release variety of neuromodulators and 
neuroactive substances such as; ROS (3), nitric oxide 
(NO), peroxynitrite [12], prostaglandins (PGs) [13], 
pro-IC (IL-1β and TNF-α) (14) which have been 
implicated directly in the induction of NP. Glutamate 
has been reported to be one of the excitatory amino 
acid released from neurons and activate microglia 
(15). A study reported that the development of 
diabetes-induced hyperalgesia involves spinal 
mitogen-activated protein kinase (MAPK) activation in 
neurons and microglia via N-methyl-D-aspartate 
(NMDA) dependent mechanisms [9].  
Apart from glycemic control, a corresponding wide 
range of treatments have been employed to treat 
patients with NP, such as: opioid, antiepileptics, 
tricyclic antidepressants, serotonin reuptake inhibitors, 
NMDA receptor antagonists, lipoic acid, cannabinoids 
and capsaicin [16]. The most commonly used drug to 
treat DNP is gabapentin, duloxetine, pregabalin and 
lidocaine patches (5%) [16]. Drug therapy of DN is 
often limited and unsatisfactory due to partial 
effectiveness and associated side effects and further 
their development is hindered due to incomplete 
knowledge about induction and maintenance of DN. 
Epidemiological studies have revealed that a diet rich 
in plant-derived foods has a protective effect on 
human health. Kaempferol (3,5,7-trihydroxy-2-(4-
hydroxyphenyl)-4H-1-benzopyran-4-one) is a 
flavonoid  found in many edible plants (e.g. tea, 
broccoli, cabbage, kale, beans, endive, leek, tomato, 
strawberries, grapes, Ginkgo biloba, Tilia spp, 
Equisetum spp, Moringa oleifera, Sophora japonica, 
cruciferous vegetables, some edible berries and 
propolis) [17]. Kaempferol has a wide range of 
pharmacological activities, including anti-oxidant, anti-
inflammatory, antimicrobial, anticancer, 
cardioprotective, neuroprotective, antidiabetic, anti-
osteoporotic, anxiolytic, analgesic, anti-hypertensive, 
antiallergic activities and lipolytic effect [17].  
Therefore, the present work was aimed to 
estimate the effect of kaempferol on experimental DN 
in mice. 
 
Materials and Methods 
Chemicals 
Kaempferol, STZ, dimethyl sulfoxide (DMSO) 
and formalin (37% formaldehyde) were obtained from 
Sigma-Aldrich Chemie Gmbh, Steinheim, Germany. 
Rat IL-1β and rat TNF-α ELISA kit were from 
BioSource International Inc., Camarillo, CA, USA. 
Unless stated, all other chemicals and biochemical 
reagents of highest analytical grade quality were 
used. 
 
Animals 
Male Swiss mice (25–30 g) obtained from our 
animal house facility was used in the present study. 
The animals were housed under optimal laboratory 
conditions, maintained on 12 h light and dark cycle 
with food and water ad libitum. Animals were 
acclimatized to laboratory conditions before the tests. 
All experiments were carried out between 9:00 and 
17:00 o’clock and using age-matched animals in an 
attempt to avoid variability between experimental 
groups. Animal body weight was measured at the 
beginning and at the end of the experiment. The 
experimental protocols were approved by the 
Institutional Animal Ethics Committee (IAEC) of Taif 
University, Taif, Saudi Arabia (protocol No. IACE/RES 
1-434-2205, Dated 15 December 2012). Animals were 
acclimatized to laboratory conditions for 15 days 
before starting the experiment. Animals were 
observed for general health and suitability for testing 
during this period. 
 
Induction and assessment of diabetes in mice 
Mice were treated with a single dose of STZ 
(200 mg/kg) in citrate buffer (pH 4.4, 0.1 M) 
intraperitoneally (18). Mice were considered as 
diabetic if their blood glucose levels were above 200 
mg/dl after 48 h of STZ-injection. 
 
Study protocol 
Fifteen days after induction of diabetes, mice 
were randomly divided into 6 groups (8/each). Normal 
and DM were treated orally (once daily) with DMSO or 
Kaempferol (25, 50 and 100 mg/kg bwt, freshly 
prepared in DMSO), in a constant volume of 1 ml/100 
g, started on day 16
th
 after induction of diabetes and 
continued for the next 21 days [19, 20]. 
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First group; normal mice were treated with DMSO (V).  
Second group; DM were treated with DMSO (D).  
Third group; normal mice were treated with 
kaempferol (100 mg/kg) (V+K100).  
Fourth, fifth and sixth groups; DM were treated with 
kaempferol (25, 50 and 100 mg/kg, respectively) 
(D+K25, D+K50 & D+K100) [19, 21].  
The behavioral nociceptive reaction was 
assessed at 60 min after kaempferol or DMSO 
treatment [22]. All of the behavioral parameters were 
evaluated on days 1 (24 h after induction of diabetes) 
and 15 (the day before DMSO or kaempferol 
treatment) using 2 h as a time interval, then continued 
on a different days for each parameter as an 
explained in the methods section and results to avoid 
results overlapping and tissue damage.  
 
Behavioral test paradigm 
Cold allodynia: Right hind paw of the mice 
was dipped in water bath maintained at 10 ± 0.5°C 
(non-noxious stimulus) [23]. The response latency of 
the right hind paw withdrawal to cold stimulation was 
estimated thrice with a 5 min interval between (the 
paw was dried with soft tissue in between) and 
averaged on days 1, 15, 20, 25, 30 and 35 of the 
experiment.  A fifteen second was imposed as a cut-
off time to avoid tissue damage. A marked reduction 
in paw withdrawal latency (PWL) indicated allodynia. 
Tail immersion (Thermal allodynia) test: Mice 
tail was immersed in a water bath maintained at 52.5 
± 0.5 °C until tail withdrawal (flicking response) or 
signs of struggle were observed, on days 1, 15, 21, 
27, 32 and 36 of the experiment. The baseline latency 
of tail withdrawal from thermal source was established 
three times, using 5 min as a time interval (the tail was 
dried in between) and averaged. A cut-off time of 12 s 
was used to avoid tissue damage. The decreased 
response latency (tail withdrawal time) referred to 
hyperalgesia and is attributed to central mechanisms. 
In the tail-flick test, the delay in removing the tail from 
noxious stimuli is evaluated reflecting the activity of 
simple spinal reflex arc (24). Moreover, the paw 
withdrawal responses to noxious thermal stimuli 
(hyperalgesia) reveal supraspinal sensory processing 
(24). 
Paw immersion test: The hyperalgesic 
response on the paw immersion test is referred to 
result from central and peripheral mechanisms. 
Thermal hypersensitivity associated with NP was 
measured using mean paw withdrawal latencies of the 
right hind-paw when immersed in water bath 
maintained at 52.5 ± 0.5 °C, on days 1, 15, 22, 28, 31 
and 34 of the experiment. The response latency time 
of right hind-paw was estimated three times using 5 
min as a time interval and averaged. Fifteen seconds 
was used as a cut-off time to prevent paw injury. 
Reduction in the response latency indicates the 
development of thermal hyperalgesia [25]. 
Hot plate test:  The hyperalgesic response 
on the hot plate is considered to result from a 
combination of central and peripheral mechanisms 
[26, 27]. Mice were placed individually on a hot plate 
adjusted to 52 ± 1 °C. The latency of hind-paw licking 
or jumping was determined using a timer as an index 
of the pain threshold, on days 1, 15, 19, 24, 29 and 33 
of the experiment. A cut-off time of 60 s was used to 
prevent tissue damage.   
Formalin-induced pain and edema test 
(moderate, tonic, inflammatory pain): Mice were left in 
the observation cage for 30 min to acclimate before 
starting the experiment (day 37
th
). Animals were 
injected with 20 µl of formalin (5% in saline), under the 
skin of the dorsal surface of the right hind-paw and 
returned into the observation (10 x 20 x 24 cm). Every 
fifth seconds the observation of pain-related behaviors 
(lifting, licking or no pain of the injected paw) was 
recorded in the early phase (0-5 min) and in the late 
phase (30-35 min) after the formalin injection. Results 
were expressed as the sum of flinching response 
(lifting & licking) in the two phases. Edema formation 
was evaluated by measuring the thickness of the right 
hind-paw (before and after formalin injection) using a 
dial caliper. Edema size was expressed as the 
difference in paw thickness (in millimeter) ((26, 27). In 
the formalin test, phase 1 responses reflect acute 
nociceptive pain similar to the chemical nociceptive 
tests whereas phase 2 responses are attributed to the 
combination of on-going inflammatory-related afferent 
input from peripheral tissue and functional changes in 
the dorsal horn of the spinal cord. 
 
Biochemical parameters 
Twenty four hours after the last treatment 
(day 38
th
), blood was collected and used for serum 
preparation.  
Blood glucose: Serum glucose was estimated 
using enzymatic assay method [28].  
Pro-inflammatory cytokines: IL-1β and TNF-α 
concentration were determined in the serum using rat 
ELISA kit according to manufacturer's instructions [29] 
at 450 nm. Values were obtained from a standard 
curve and expressed as pg/ml.  
Markers of oxidative stress: Nitrite was 
assayed spectrophotometrically using Griess reagent 
[30]. Glutathione (GSH) and malondialdehyde (MDA) 
levels were estimated in the mice serum according to 
the methods described previously by Draper and 
Hadley [31] and Ellman [32] respectively. Serum GSH 
and MDA concentration were measured 
spectrophotometrically [at 412 nm (GSH) and 532 nm 
(MDA)] from a standard curve that was obtained from 
freshly prepared standard solution of GSH and 
1,1,3,3-tetramethoxypropane respectively.  
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Statistical analysis of data 
Data are expressed as mean ± SEM and 
statistically analyzed using one-way ANOVA followed 
by Tukey’s test. P ≤ 0.05 was considered as 
statistically significant. 
 
Results 
Treatment of normal mice with kaempferol 
(100 mg/kg) had no significant effect on all behavior 
and biochemical parameters. 
 
Streptozotocin injection and induction of 
diabetes 
More than 90 % of the animals were diabetic 
48 h after STZ administration as indicated by serum 
glucose levels more than 200 mg/dl and remained 
high at the end of the experiment (Table 1). 
Table 1: Effect of kaempferol on body weight and blood 
glucose in normal and diabetic mice. 
Treatment 
(mg/kg) 
Body weight (g) Blood glucose (mg/dl) 
Initial Final Initial Final 
V 27.00 ± 0.65 34.88 ± 0.74 100.38 ± 3.31 98.88 ± 2.93 
D 27.88 ± 0.48 23.38 ± 0.42
a
 236.25 ± 6.16
a
 320.63 ± 5.72
a
 
V+K100 27.13 ± 0.55 36.38 ± 0.68
b
 100.25 ± 3.73
b
 99.25 ± 3.56
b
 
D+K25 26.25 ± 0.49 31.38 ± 0.82
a,b,c
 238.50 ± 2.56
a,c
 315.50 ± 6.86
a
 
D+K50 26.38 ± 0.53 33.88 ± 0.74
b
 237.38 ± 4.65
a,c
 206.63 ± 4.15
a,b
 
D+K100 28.13 ± 0.48 36.13 ± 0.72
b,d
 239.25 ± 5.77
a,c
 149.00 ± 3.60
a,b
 
 
Data are the means ± SEM (n=8). V: vehicle control; D: diabetic group; K: kaempferol. 
a
P < 
0.05 as compared to vehicle control group; 
b
P < 0.05 as compared to diabetic group; 
c
P < 
0.05 as compared to V+K100 group; 
d
P < 0.05 as compared to D+K25 group. Kaempferol 
was given orally at the recommended doses for 21 days (started on day 16
th
 of the 
experiment). 
 
Effect of kaempferol on body weight and 
blood glucose levels  
At the end of the experiment, kaempferol 
treated (25, 50 or 100 mg/kg) and untreated DM 
exhibited significantly increased glucose levels 
compared with the control mice. While, administration 
of kaempferol at doses 50 or 100 mg/kg induced a 
marked decrease in the blood glucose compared to 
DM. Interestingly, there was a significant difference in 
blood glucose levels between kaempferol doses. 
Moreover, diabetic-untreated and kaempferol treated 
(25 mg/kg) mice exhibited a marked decrease in the 
body weight gain compared to control animals, while 
kaempferol at doses 50 and 100 mg/kg normalized 
body weight gain in DM (Table 1). 
 
Effect of kaempferol on pro-inflammatory 
cytokines and markers of oxidative stress 
Free radicals and pro-IC significantly 
increased in DM in response to hyperglycemia, 
causing oxidative and nitrosative stress, which play an 
important role in central sensitization. Thus we also 
evaluated the effect of kaempferol on the markers of 
oxidative and nitrosative stress as well as pro-IC.  
Chronic hyperglycemia induced a marked 
increase in MDA and nitrite levels, accompanied with 
reduction of GSH content in serum. Systemic 
administration of kaempferol during the development 
of DNP significantly attenuated oxidative and 
nitrosative stresses in a dose dependant manner 
(Table 2).  
 
Table 2: Effect of kaempferol on serum GSH, MDA, NO, TNF-α, IL-1β in normal and diabetic mice. 
Treatment 
(mg/kg) 
GSH 
(µmol/ml) 
MDA 
(nmol/ml) 
NO 
(ng/ml) 
TNF-α 
(pg/ml) 
IL-1β 
(pg/ml) 
V 202.13 ± 9.42 2.54 ± 0.20 155.00 ±  6.14 50.88 ±  2.42 6.63 ± 0.68 
D 63.13 ± 6.41
a
 6.36 ± 0.62
a
 338.63 ± 11.98
a
 552.75 ± 22.93
a
 25.50 ± 1.21
a
 
V+K100 224.38 ± 10.35
b
 2.44 ± 0.18
b
 148.63 ± 3.19
b
 51.00 ± 2.56
b
 6.13 ± 0.40
b
 
D+K25 91.88 ± 9.09
a,c
 6.06 ± 0.56
a,c
 223.25 ± 19.74
a,b,c
 468.88 ± 24.94
a,b,c
 19.75 ± 1.05
a,b,c
 
D+K50 202.50 ± 11.58
b,d
 4.66 ± 0.33
a,b,c
 191.38 ± 6.26
b
 202.50 ± 11.58
a,b,c,d
 13.75 ± 0.77
a,b,c,d
 
D+K100 222.38 ± 11.63
b,d
 2.81 ± 0.19
b,d,e
 157.00 ± 6.72
b,d
 57.88 ± 2.67
b,d,e
 6.63 ± 0.38
b,d,e
 
Data are the means ± SEM (n=8). V: vehicle control; D: diabetic group; K: kaempferol. 
a
P < 0.05 as compared to vehicle control group; 
b
P < 0.05 as compared to diabetic group; 
c
P < 0.05 
as compared to V+K100 group; 
d
P < 0.05 as compared to D+K25 group; 
e
P < 0.05 as compared to D+K50 group;. Kaempferol was given orally at the recommended doses for 21 days 
(started on day 16
th
 of the experiment). 
 
The serum levels of IL-1β and TNF-α (Table 
2) were significantly elevated in DM when compared 
to that of vehicle-treated control mice. However, the 
concentrations of these cytokines were significantly 
lower in DM that had been treated with kaempferol 
(25, 50 or 100 mg/kg) in a dose dependant manner. 
There was a significant difference in kaempferol 
doses in pro-IC and, markers for oxidative and 
nitrosactive stress (Table 2). 
 
Effect of kaempferol on formalin-induced 
flinching and edema size 
Table 3 showed that all mice challenged with 
formalin subcutaneously into the dorsal surface of the 
right hind-paw had characteristic biphasic response 
with an early phase 1 and a late phase 2 separated by 
a quiescent phase as well as increased paw 
thickness. There was a significant difference in the 
sum of flinches counted in phase 1, phase 2 and 
edema size between age-matched control and 
diabetic animals on day 38
th
. Whereas systemic 
administration of kaempferol (50 or 100 mg/kg) to DM 
significantly decreased formalin-induced nociceptive 
behavior in phase 1, phase 2 and edema size as 
compared to vehicle treated DM. DM treated with 
Kaempferol (25 mg/kg) had no significant changes in 
the phase 1, phase2 and edema size compared to the 
diabetic untreated mice. 
 
Effect of kaempferol on cold allodynia 
The threshold for cold stimuli was markedly 
reduced at day 15 in DM and maintained to the end of 
the experiment compared to non DM. Diabetic  
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Table 3: Effect of kaempferol on nociceptive responses and 
edema size in the formalin test indicative of hyperalgesia in 
development of diabetic neuropathy. 
Treatment 
(mg/kg) 
Number of flinches 
            Edema size (mm) 
Early phase Late phase 
V 39.75 ± 1.56 24.25 ± 0.49 1.74 ± 0.06 
D 54.00 ± 1.44
a
 35.38 ± 0.50
a
 2.93 ± 0.03
a
 
V+K100 37.38 ± 1.46
b
 24.00 ± 0.38
b
 1.61 ± 0.13
b
 
D+K25 50.88 ± 1.88
a,c
 34.88 ± 1.29
a,c
 2.46 ± 0.22
a,c
 
D+K50 45.13 ± 0.90
b,c
 27.75 ± 1.80
b,d
 1.99 ± 0.10
b,c
 
D+K100 41.00 ± 1.99
b,d
 23.75 ± 1.36
b,d
 1.76 ± 0.06
b,c,d
 
Data are the means ± SEM (n=8). V: vehicle control group; D: diabetic group; K: 
kaempferol. 
a
P < 0.05 as compared to vehicle control group; 
b
P < 0.05 as compared to 
diabetic group; 
c
P < 0.05 as compared to V+K100 group; 
d
P < 0.05 as compared to D+K25 
group. Kaempferol was given orally at the recommended doses for 21 days (started on 
day 16
th
 of the experiment). 
 
animals exhibited a significant decrease in pain 
threshold from non-noxious stimuli compared to age-
matched, vehicle-treated group. Systemic 
administration of kaempferol (50 or 100 mg/kg) 
significantly attenuated the development of 
hypersensitivity to cold stimulus in DM as compared to 
vehicle-treated diabetic group. The effect of 
kaempferol on diabetes induced-hypersensitivity in the 
cold non-noxious stimuli was dose dependent (Fig 
1A).  
 
(A) Cold Allodynia 
 
(B) Tail Immersion 
 
(C) Paw Immersion 
 
(D) Hot-plate 
 
Figure 1: Effect of kaempferol at different doses on (A) PWL to cold stimuli (cold allodynia); (B) tail withdrawal latency to thermal stimuli (Tail 
immersion); (C) PWL to thermal stimuli (Paw immersion) and (D) PWL to thermal stimuli (Hot plat) in mice indicative of thermal hyperalgesia 
in development of DN. Data are the means ± SEM (n=8). V: vehicle control group; D: diabetic group; K: kaempferol. 
a
P < 0.05 as compared 
to vehicle control group; 
b
P < 0.05 as compared to diabetic group; 
c
P < 0.05 as compared to V+K100 group; 
d
P < 0.05 as compared to 
D+K25 group; 
e
P < 0.05 as compared to D+K50 group;. Kaempferol was given orally at the recommended doses for 21 days (started on day 
16
th
 of the experiment). Fig. 1 showed that diabetic animals exhibited a significant increase in pain sensation in all parameters tested. 
Administration of kaempferol significantly elevated the pain threshold in all parameters in a dose dependent manner. 
 
Effect of kaempferol on thermal hyperalgesia 
The threshold for thermal hyperalgesia was 
significantly decreased at day 15 and continued to 
develop down to day 38
th
 after STZ injection as 
compared to vehicle treated age-matched non-
diabetic animals. While, kaempferol (25, 50 or 100 
mg/kg) markedly prevented the development of 
hyperalgesia in DM as compared to vehicle-treated 
DM. Moreover, the thermal pain threshold was 
significantly lower in animals treated with 25 mg/kg 
kaempferol as compared to normal mice. Interestingly, 
The effect of kaempferol on the thermal pain threshold 
was dose and time dependent: 25 mg/kg was effective 
at day 32, 31 and 33 for tail immersion, paw 
immersion and hot-plate respectively; 50 or 100 mg/kg 
was effective at day 27, 22 and 24 for tail immersion, 
paw immersion and hot-plate respectively (Fig. 1B, 1C 
& 1D). 
 
 
 
Discussion  
The mechanisms of progressive nerve fiber 
loss in diabetes, including polyol pathway, glycation, 
ROS, pro-IC and altered protein kinase C activity, 
which affect cellular proteins, gene expression and 
receptor expression and resulting in diabetic 
complications [33]. 
In the present study, DM had significantly 
lower nociceptive threshold and body weight gain, 
with higher blood glucose, pro-IC and OS. Pre-
treatment of DM with kaempferol significantly 
increased nociceptive threshold and improved body 
weight gain, with decreased pro-IC and OS. Thus, it is 
clear from the behavioral studies that kaempferol 
attenuated the development of DN and suggest the 
involvement of activated microglia, inflammatory 
cytokine and OS in nociceptor hypersensitization in 
diabetes.  
This is in line with previous observation 
reported that,  STZ-injected mice had increased pain 
Abo-Salem OM. Kaempferol Attenuates Diabetic Neuropathy 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Sep 15; 2(3):424-430.                                                                                                                                                                         429 
 
sensation in a model of cold allodynia, thermal 
hyperalgesia, formalin-evoked flinching and formalin 
increased edema size [24]. Hyperglycemia induces 
OS through different pathways such as increased 
aldose reductase activity, glycation, protein kinase C 
activity, prostanoids production and superoxide 
generation [4, 33, 34]. All these pathways converge in 
the production of OS and these results in NF-κB [35] 
and TNF-α activation [36] and cycloxygenase-2 (COX-
2) gene expression [37]. Indeed, activated microglial 
cells in the central nervous system are an important 
source of free radicals [13], express inducible nitric 
oxide synthase (iNOS) [12] in response to pro-IC. 
ROS, nitrosative and OS have been implicated in the 
central sensitization, development and maintenance 
of DN [2, 5], which are attenuated by antioxidants 
GSH, α-lipoic acid, taurine [2]. Previous studies 
reported that kaempferol induce-neuroprotective effect 
through suppression of iNOS, scavenge superoxide 
and peroxynitrite in glial cells [38]. Furthermore, it 
attenuate LPS-induced inflammatory mediators (NO, 
prostaglandine-2, TNF-α, IL-1β, ROS and 
phagocytosis) in the microglial cells through down-
regulation of Toll-like receptors-4, NF-kB, p38 MAPK, 
JNK and AKT [39]. Several lines of evidence support 
the neurotoxic role of NO and prostaglandine-2 in 
neuronal cell death, which can be attenuated by using 
NOS inhibitors and NSAIDs [4, 40]. The present study 
provides evidence that attenuation of hypersensitivity 
in diabetes by kaempferol is accompanied by reduced 
OS and further suggesting the role of ROS and 
reactive nitrogen species in the activation of microglia 
and vice versa in the development of DN.  
Hyperglycemia induce cytokine release (TNF-
α and IL-1β), which promotes neuronal injury and 
demyelinating process [6, 36]. TNF-α is a key 
downstream mediator in inflammatory responses, and 
IL-1β is known to be the major microglial signal that 
promotes the cascade of glial cell reactions. 
Accumulating data indicate that TNF-α, IL-1β, ROS 
and peroxynitrite directly activate microglia and 
induced NP [3, 10, 12]. In addition, pro-IC release 
lead to accumulation of free radicals and activate 
enzymes like COX-2 and iNOS, further releasing PGs 
and NO, well known mediators involved in spinal 
hypersensitization [41]. These observations combined 
with our results, that showed significant increase in 
serum IL-1β and TNF-α level in the development of 
DN which was markedly attenuated by kaempferol 
treatment [8, 22]. Moreover, Kaempferol inhibits the 
gene expression of LPS-induced TNF-α and IL-1β [42] 
and inhibits pro-IC, COX-2 and iNOS, through 
accumulation of IκB the inhibitory subunit for NF-κB 
[39, 43]. Further, it provides significant 
neuroprotection, anti-inflammatory and antinociceptive 
effects of kaempferol [22]. Consistent with previous 
reports, kaempferol had no effect on nociceptive 
threshold in tail immersion and hot plate which further 
supports that the microglia are not activated in the 
normal animals [21]. Moreover, kaempferol had no 
effect on basal responses indicating that the effect in 
DM is not due to analgesic or hypoalgesic effect only 
[20, 21, 22]. These data along with the results of the 
present study suggest that kaempferol decreases pro-
inflammatory cytokine levels that are involved in 
attenuating DN.  
Pain has been thought to arise primarily from 
the dysfunction of neurons. Growing body of data 
implicate that the activation of non-neuronal cells 
(microglia and astrocytes) play an important role in 
central sensitization [8]. Moreover, It was reported 
that, increased activation of the glial cells, particularly 
microglia in the spinal cord [9], retina [10] and 
hypothalamus [11] in uncontrolled hyperglycemic. 
Activated microglia release variety of neuromodulators 
and neuroactive substances like ROS [3], NO and 
peroxynitrite [12], PGs [13], and pro-IC (IL-1β and 
TNF-α) [14] which have been implicated directly in the 
induction of DNP. Spinal administration of activated 
microglia produced hypersensitivity, but not quiescent 
microglia and activated astroglia which indicated that 
activated microglia are involved in spinal sensitization 
[44]. Glutamate and MAPK activate microglia and 
induced diabetic hyperalgesia via NMDA dependent 
mechanisms [9, 15]. Moreover, inhibitors of iNOS and 
COX-2 expression have been found to exert 
neuroprotective effects in Parkinson’s and Alzheimer 
disease [37]. These findings suggest that kaempferol 
may be a promising candidate to inhibit the primary 
steps in the neuroinflammatory pathway. Because, 
kaempferol is without any effect on neurons and 
astrocytes, it seems likely that the antihyperalgesic 
and antiallodynic effects of kaempferol in attenuating 
behavioral hypersensitivity could be attributed to its 
ability to suppress the activation of microglia during 
the course of disease state [21, 39]. 
 In conclusion, the results demonstrate that 
kaempferol attenuates the development of 
hyperalgesia and allodynia in STZ model of DNP 
probably by inhibiting microglial activation and partly 
by decreasing the inflammatory mediators and 
oxidative stress. Moreover, further studies are 
warranted to explore the exact mechanism of 
kaempferol’s anti-nociceptive effect. 
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